Candiani MFernandez HHoshiai HOlive D.LSchweppe K.-WYU-SHIH YANG2020-02-172020-02-1720051699-3993https://scholars.lib.ntu.edu.tw/handle/123456789/460331[SDGs]SDG3androstenedione; antibiotic agent; aromatase; biological marker; CA 125 antigen; conjugated estrogen; cyclooxygenase 2; cyclooxygenase 2 inhibitor; cytochrome P450; danazol; estradiol; estrogen; estrogen receptor; estrone; gestagen; gonadorelin agonist; Ki 67 antigen; levonorgestrel; lipid; medrogestone; medroxyprogesterone acetate; nonsteroid antiinflammatory agent; norethisterone; oral contraceptive agent; progesterone; progesterone receptor; testosterone; testosterone 17beta dehydrogenase; tibolone; unindexed drug; gonadorelin; add on therapy; age distribution; antibiotic therapy; clinical trial; conference paper; cost effectiveness analysis; depression; diagnostic accuracy; disease severity; drug efficacy; drug megadose; drug safety; drug tolerability; dysmenorrhea; endometriosis; France; headache; heart disease; histopathology; hot flush; human; hyperhidrosis; incidence; laparoscopy; long term care; low drug dose; mood disorder; pelvis pain syndrome; practice guideline; prescription; sensitivity and specificity; spotting; treatment indication; vagina disease; vagina dryness; adult; advisory committee; article; drug potentiation; endometriosis; female; middle aged; pelvis pain syndrome; Adult; Advisory Committees; Endometriosis; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Pelvic Painconference paper162002242-s2.0-23444438476